Understanding Stem Cell Immunogenicity in Therapeutic Applications

Trends in Immunology

Volumn 37, Issue 1, 2016, Pages 5-16

  Wood, Kathryn J ^a   Issa, Fadi ^a   Hester, Joanna ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

CELL DIFFERENTIATION; CELL FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; ANIMAL; IMMUNITY; IMMUNOLOGY; NUCLEAR REPROGRAMMING; STEM CELL TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; HUMANS; IMMUNITY; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84952864323     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.11.005     Document Type: Review

References (70)

1. Deuse T., et al. SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. Cell Stem Cell 2015, 16:33-38.
2. Zhao T., et al. Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell 2015, 17:353-359.
3. Boyd A.S., Wood K.J. Variation in MHC expression between undifferentiated mouse ES cells and ES cell-derived insulin-producing cell clusters. Transplantation 2009, 87:1300-1304.
4. Wu D.C., et al. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 2008, 26:1939-1950.
5. Chen H-F., et al. Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and their derivatives. Cell Transplant. 2015, 24:845-864.
6. Frenzel L.P., et al. Role of natural-killer group 2 Member D Ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes. Stem Cells 2009, 27:307-316.
7. Dressel R., et al. The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS ONE 2008, 3:e2622.
8. Swijnenburg R-J., et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12991-12996.
9. Drukker M., et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9864-9869.
10. Ma M., et al. Major histocompatibility complex-i expression on embryonic stem cell-derived vascular progenitor cells is critical for syngeneic transplant survival. Stem Cells 2010, 28:1465-1475.
11. Wood K.J., Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012, 93:1-10.
12. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. 1997, 157:125-140.
13. Robertson N.J., et al. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20920-20925.
14. Ridge P.G., et al. Mitochondrial genomic variation associated with higher mitochondrial copy number: the Cache County Study on Memory Health and Aging. BMC Bioinformatics 2014, 15:S6.
15. Tachibana M., et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013, 153:1228-1238.
16. Zhao T., et al. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
17. Ghosh Z., et al. Dissecting the oncogenic potential of human embryonic and induced pluripotent stem cell derivatives. Cancer Res. 2011, 71:5030-5039.
18. Okita K., et al. Immunogenicity of induced pluripotent stem cells. Circ. Res. 2011, 109:720-721.
19. Thanasegaran S., et al. No immunogenicity of IPS cells in syngeneic host studied by in vivo injection and 3D scaffold experiments. Biomed Res. Int. 2013, 2013:7.
20. de Almeida P.E., et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat. Commun. 2014, 5:3903.
21. Araki R., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494:100-104.
22. Guha P., et al. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013, 12:407-412.
23. Hong S.G., et al. Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model. Cell Rep. 2014, 7:1298-1309.
24. Hallett P.J., et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 2015, 16:269-274.
25. Morizane A., et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Rep. 2013, 1:283-292.
26. Doi D., et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep. 2014, 2:337-350.
27. Ghosh Z., et al. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS ONE 2010, 5:e8975.
28. Awe J.P., et al. Putative immunogenicity expression profiling using human pluripotent stem cells and derivatives. Stem Cells Transl. Med. 2015, 4:136-145.
29. Marks H., et al. The transcriptional and epigenomic foundations of ground state pluripotency. Cell 2012, 149:590-604.
30. Koyanagi-Aoi M., et al. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:20569-20574.
31. Chung T-L., et al. Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells. Stem Cells 2010, 28:1782-1793.
32. Rong Z., et al. An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell 2014, 14:121-130.
33. Kamao H., et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep. 2014, 2:205-218.
34. Sun J., et al. Protective effects of human iPS-derived retinal pigmented epithelial cells in comparison with human mesenchymal stromal cells and human neural stem cells on the degenerating retina in rd1 mice. Stem Cells 2015, 33:1543-1553.
35. Mölne J., et al. Blood group ABO antigen expression in human embryonic stem cells and in differentiated hepatocyte- and cardiomyocyte-like cells. Transplantation 2008, 86:1407-1413.
36. Wang J., et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotech. 2008, 26:901-908.
37. Földes G., et al. Innate immunity in human embryonic stem cells: comparison with adult human endothelial cells. PLoS ONE 2010, 5:e10501.
38. Zampetaki A., et al. TLR4 expression in mouse embryonic stem cells and in stem cell-derived vascular cells is regulated by epigenetic modifications. Biochem. Biophys. Res. Commun. 2006, 347:89-99.
39. Lee S-H., et al. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells 2009, 27:1604-1615.
40. Boyd A.S., Wood K.J. Characteristics of the early immune response following transplantation of mouse ES cell derived insulin-producing cell clusters. PLoS ONE 2010, 5:e10965.
41. Pashuck E.T., Stevens M.M. Designing regenerative biomaterial therapies for the clinic. Sci. Transl. Med. 2012, 4:160sr4.
42. Elliott M.J., et al. Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study. Lancet 2012, 380:994-1000.
43. Taylor C.J., et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 2005, 366:2019-2025.
44. Wilmut I., et al. Development of a global network of induced pluripotent stem cell haplobanks. Regen. Med. 2015, 10:235-238.
45. Deuse T., et al. Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells. J. Cell Sci. 2011, 124:3029-3037.
46. English K., et al. Mesoangioblasts suppress T cell proliferatin through IDO and PGE-2 dependent mechanisms. Stem Cells Dev. 2013, 22:512-523.
47. Li O., et al. Human iPSC-derived mesoangioblasts, like their tissue derived counterparts, suppress T cell proliferation through IDO- and PGE-2 dependent pathways. F1000 Res. 2014, 2:24.
48. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 2004, 351:2715-2729.
49. Pearl J.I., et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011, 8:309-317.
50. Krenzien F., et al. A rationale for age-adapted immunosuppression in organ transplantation. Transplantation 2015, 99:2258-2268.
51. Ford M.L., Larsen C.P. translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol. Rev. 2009, 229:294-306.
52. Grinnemo K-H., et al. Immunogenicity of human embryonic stem cells. Cell Tissue Res. 2008, 331:67-78.
53. Grinnemo K-H., et al. Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. Stem Cells 2008, 26:1850-1857.
54. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat. Immunol. Rev. 2003, 3:199-210.
55. Nadig S.N., et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat. Med. 2010, 16:809-813.
56. Issa F., et al. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanised mouse model. Transplantation 2010, 90:1321-1327.
57. Wu D.C., et al. Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. Transplantation 2013, 96:707-716.
58. Ljung K., et al. Costimulation blockade induces Foxp3(+) regulatory T cells to human embryonic stem cells. Biores. Open Access 2013, 2:455-458.
59. Haque R., et al. Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J. Immunol. 2012, 189:1228-1236.
60. Wood K.J., et al. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 2012, 12:417-430.
61. Kawai T., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 2008, 358:353-361.
62. Scandling J.D., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 2008, 358:362-368.
63. Kawai T., et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am. J. Transplant. 2014, 14:1599-1611.
64. Leventhal J., et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 2012, 4:124ra28.
65. Ezzelarab M., Thomson A.W. Tolerogenic dendritic cells and their role in transplantation. Semin. Immunol. 2011, 23:252-263.
66. Senju S., et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells 2009, 27:1021-1031.
67. + progenitors. J. Clin. Invest. 2009, 119:2818-2829.
68. Yates S.F., et al. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J. Immunol. 2007, 179:967-976.
69. Verda L., et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 2008, 26:381-386.
70. Jaenisch R., Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008, 132:567-582.